🎉 M&A multiples are live!
Check it out!

Newron Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Newron Pharmaceuticals and similar public comparables like Julphar, Galapagos, and Vivoryon Therapeutics.

Newron Pharmaceuticals Overview

About Newron Pharmaceuticals

Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of therapies for patients with diseases of the central and peripheral nervous system. Geographically the research and development activities are performed in Italy and the United States.


Founded

1999

HQ

Switzerland
Employees

22

Website

newron.com

Financials

LTM Revenue $40.8M

LTM EBITDA $16.4M

EV

$180M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Newron Pharmaceuticals Financials

Newron Pharmaceuticals has a last 12-month revenue of $40.8M and a last 12-month EBITDA of $16.4M.

In the most recent fiscal year, Newron Pharmaceuticals achieved revenue of $10.2M and an EBITDA of -$13.4M.

Newron Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Newron Pharmaceuticals valuation multiples based on analyst estimates

Newron Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $6.9M $10.2M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$15.1M -$13.4M XXX XXX XXX
EBITDA Margin -219% -131% XXX XXX XXX
Net Profit -$16.9M -$19.8M XXX XXX XXX
Net Margin -245% -193% XXX XXX XXX
Net Debt $19.8M $35.9M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Newron Pharmaceuticals Stock Performance

As of April 15, 2025, Newron Pharmaceuticals's stock price is CHF 6 (or $7).

Newron Pharmaceuticals has current market cap of CHF 125M (or $141M), and EV of CHF 159M (or $180M).

See Newron Pharmaceuticals trading valuation data

Newron Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$180M $141M XXX XXX XXX XXX $0.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Newron Pharmaceuticals Valuation Multiples

As of April 15, 2025, Newron Pharmaceuticals has market cap of $141M and EV of $180M.

Newron Pharmaceuticals's trades at 4.2x LTM EV/Revenue multiple, and 10.4x LTM EBITDA.

Analysts estimate Newron Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Newron Pharmaceuticals and 10K+ public comps

Newron Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $180M XXX XXX XXX
EV/Revenue 17.5x XXX XXX XXX
EV/EBITDA -13.4x XXX XXX XXX
P/E -7.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -15.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Newron Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Newron Pharmaceuticals Valuation Multiples

Newron Pharmaceuticals's NTM/LTM revenue growth is -71%

Newron Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $1.1M for the same period.

Over next 12 months, Newron Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Newron Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Newron Pharmaceuticals and other 10K+ public comps

Newron Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 49% XXX XXX XXX XXX
EBITDA Margin -131% XXX XXX XXX XXX
EBITDA Growth -11% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -202% XXX XXX XXX XXX
Revenue per Employee $0.5M XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue 1% XXX XXX XXX XXX
G&A Expenses to Revenue 44% XXX XXX XXX XXX
R&D Expenses to Revenue 145% XXX XXX XXX XXX
Opex to Revenue 228% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Newron Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Newron Pharmaceuticals M&A and Investment Activity

Newron Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Newron Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Newron Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Newron Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Newron Pharmaceuticals

When was Newron Pharmaceuticals founded? Newron Pharmaceuticals was founded in 1999.
Where is Newron Pharmaceuticals headquartered? Newron Pharmaceuticals is headquartered in Switzerland.
How many employees does Newron Pharmaceuticals have? As of today, Newron Pharmaceuticals has 22 employees.
Is Newron Pharmaceuticals publicy listed? Yes, Newron Pharmaceuticals is a public company listed on SWX.
What is the stock symbol of Newron Pharmaceuticals? Newron Pharmaceuticals trades under NWRN ticker.
When did Newron Pharmaceuticals go public? Newron Pharmaceuticals went public in 2006.
Who are competitors of Newron Pharmaceuticals? Similar companies to Newron Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Newron Pharmaceuticals? Newron Pharmaceuticals's current market cap is $141M
What is the current revenue of Newron Pharmaceuticals? Newron Pharmaceuticals's last 12-month revenue is $40.8M.
What is the current EBITDA of Newron Pharmaceuticals? Newron Pharmaceuticals's last 12-month EBITDA is $16.4M.
What is the current EV/Revenue multiple of Newron Pharmaceuticals? Current revenue multiple of Newron Pharmaceuticals is 4.2x.
What is the current EV/EBITDA multiple of Newron Pharmaceuticals? Current EBITDA multiple of Newron Pharmaceuticals is 10.4x.
What is the current revenue growth of Newron Pharmaceuticals? Newron Pharmaceuticals revenue growth between 2023 and 2024 was 49%.
Is Newron Pharmaceuticals profitable? Yes, Newron Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.